Protease-activated receptors in hemostasis

Blood

Volumn 128, Issue 2, 2016, Pages 169-177

  Nieman, Marvin T ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR;

CELL MEMBRANE; ENDOTHELIUM CELL; EPIGENETICS; GENE SEQUENCE; GENETIC POLYMORPHISM; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; METABOLISM; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

CELL MEMBRANE; ENDOTHELIAL CELLS; HEMOSTASIS; PROTEIN MULTIMERIZATION; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION;

EID: 84978438161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-636472     Document Type: Review

References (122)

1. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068.
2. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene. 2001;20(13):1570-1581.
3. Ishihara H, Connolly AJ, Zeng D, et al. Proteaseactivated receptor 3 is a second thrombin receptor in humans. Nature. 1997;386(6624):502-506.
4. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690-694.
5. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human proteaseactivated receptor 4. Proc Natl Acad Sci USA. 1998;95(12):6642-6646.
6. Nystedt S, Emilsson K, Larsson AK, Strömbeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232(1):84-89.
7. Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne). 2014;5:67.
8. Lin H, Liu AP, Smith TH, Trejo J. Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev. 2013;65(4):1198-1213.
9. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015;125(19):2898-2907.
10. Gerszten RE, Chen J, Ishii M, et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368(6472):648-651.
11. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA. 1999;96(20):11023-11027.
12. Russo A, Soh UJ, Trejo J. Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv. 2009;9(2):87-96.
13. Hollenberg MD, Mihara K, Polley D, et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol. 2014;171(5):1180-1194.
14. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost. 2005;3(1):54-67.
15. Kamath P, Huntington JA, Krishnaswamy S. Ligand binding shuttles thrombin along a continuum of zymogen- and proteinase-like states. J Biol Chem. 2010;285(37):28651-28658.
16. Liu LW, Vu TK, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991;266(26):16977-16980.
17. Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem. 2000;275(52):40671-40678.
18. Nieman MT, Schmaier AH. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry. 2007;46(29):8603-8610.
19. Nieman MT. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1. Biochemistry. 2008;47(50):13279-13286.
20. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J. 2003;376(Pt 3):733-740.
21. Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E. Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci USA. 2007;104(28):11603-11608.
22. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404(6778):609-613.
23. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113(9):1244-1254.
24. De Candia E. Mechanisms of platelet activation by thrombin: a short history. Thromb Res. 2012;129(3):250-256.
25. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001;276(7):4692-4698.
26. Adam F, Verbeuren TJ, Fauchère JL, Guillin MC, Jandrot-Perrus M. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP. J Thromb Haemost. 2003;1(4):798-804.
27. Estevez B, Kim K, Delaney MK, et al. Signalingmediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood. 2016;127(5):626-636.
28. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-1882.
29. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD81 dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010;120(9):3167-3178.
30. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204(10):2439-2448.
31. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161-3172.
32. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT, Coughlin SR. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem. 2005;280(13):13122-13128.
33. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokineperturbed endothelial cells is distinct from thrombin signaling. J Biol Chem. 2005;280(20):19808-19814.
34. Feistritzer C, Lenta R, Riewald M. Proteaseactivated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost. 2005;3(12):2798-2805.
35. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105(8):3178-3184.
36. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through b-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci USA. 2011;108(50):E1372-E1380.
37. Russo A, Soh UJ, Paing MM, Arora P, Trejo J. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci USA. 2009;106(15):6393-6397.
38. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007;110(12):3909-3916.
39. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost. 2008;6(6):954-961.
40. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104(6):1740-1744.
41. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem. 2007;282(45):33022-33033.
42. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012;120(26):5237-5246.
43. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost. 2012;10(8):1675-1684.
44. Stavenuiter F, Mosnier LO. Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. Blood. 2014;124(23):3480-3489.
45. Woessner JF Jr. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann NYAcad Sci. 1999;878:388-403.
46. Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013;121(3):431-439.
47. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332-343.
48. Jaffr É F, Friedman AE, Hu Z, Mackman N, Blaxall BC. b-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24):2993-3003.
49. Urban JD, Clarke WP, Von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1-13.
50. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001;276(27):24433-24436.
51. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem. 2004;279(1):686-691.
52. Aisiku O, Peters CG, De Ceunynck K, et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood. 2015;125(12):1976-1985.
53. Dowal L, Sim DS, Dilks JR, et al. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA. 2011;108(7):2951-2956.
54. Soto AG, Smith TH, Chen B, et al. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias. Proc Natl Acad Sci USA. 2015;112(27):E3600-E3608.
55. Ayoub MA, Trinquet E, Pfleger KD, Pin JP. Differential association modes of the thrombin receptor PAR1 with Galphai1, Galpha12, and beta-arrestin 1. FASEB J. 2010;24(9):3522-3535.
56. Ayoub MA, Al-Senaidy A, Pin JP. Receptor-G protein interaction studied by bioluminescence resonance energy transfer: lessons from protease-activated receptor 1. Front Endocrinol (Lausanne). 2012;3:82.
57. Ayoub MA, Pin JP. Interaction of proteaseactivated receptor 2 with G proteins and b-arrestin 1 studied by bioluminescence resonance energy transfer. Front Endocrinol (Lausanne). 2013;4:196.
58. Whorton MR, Bokoch MP, Rasmussen SG, et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA. 2007;104(18):7682-7687.
59. Whorton MR, Jastrzebska B, Park PS, et al. Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem. 2008;283(7):4387-4394.
60. Park PS, Filipek S, Wells JW, Palczewski K. Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry. 2004;43(50):15643-15656.
61. Birdsall NJ. Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol Sci. 2010;31(11):499-508.
62. Vischer HF, Castro M, Pin JPG. G proteincoupled receptor multimers: a question still open despite the use of novel approaches. Mol Pharmacol. 2015;88(3):561-571.
63. Bouvier M, Hébert TE. Rebuttal from Michel Bouvier and Terence E. Hébert. J Physiol. 2014;592(12):2447.
64. Bouvier M, Hébert TE. CrossTalk proposal: weighing the evidence for class A GPCR dimers, the evidence favours dimers. J Physiol. 2014;592(12):2439-2441.
65. Lan TH, Liu Q, Li C, Wu G, Steyaert J, Lambert NA. BRET evidence that b2 adrenergic receptors do not oligomerize in cells. Sci Rep. 2015;5:10166.
66. Lambert NA, Javitch JA. Rebuttal from Nevin A. Lambert and Jonathan A. Javitch. J Physiol. 2014;592(12):2449.
67. Lambert NA, Javitch JA. CrossTalk opposing view: weighing the evidence for class A GPCR dimers, the jury is still out. J Physiol. 2014;592(12):2443-2445.
68. Jastrzebska B, Ringler P, Lodowski DT, et al. Rhodopsin-transducin heteropentamer: three-dimensional structure and biochemical characterization. J Struct Biol. 2011;176(3):387-394.
69. Jastrzebska B, Orban T, Golczak M, Engel A, Palczewski K. Asymmetry of the rhodopsin dimer in complex with transducin. FASEB J. 2013;27(4):1572-1584.
70. Redka DS, Heerklotz H, Wells JW. Efficacy as an intrinsic property of the M (2) muscarinic receptor in its tetrameric state. Biochemistry. 2013;52(42):7405-7427.
71. Kasai RS, Suzuki KG, Prossnitz ER, et al. Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J Cell Biol. 2011;192(3):463-480.
72. Ward RJ, Pediani JD, Godin AG, Milligan G. Regulation of oligomeric organization of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor observed by spatial intensity distribution analysis. J Biol Chem. 2015;290(20):12844-12857.
73. Patowary S, Alvarez-Curto E, Xu TR, et al. The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochem J. 2013;452(2):303-312.
74. Liste MJ, Caltabiano G, Ward RJ, Alvarez-Curto E, Marsango S, Milligan G. The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor. Mol Pharmacol. 2015;87(6):936-953.
75. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA. 2007;104(13):5662-5667.
76. Khan A, Li D, Ibrahim S, Smyth E, Woulfe DS. The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol. 2014;86(1):1-11.
77. Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J Biol Chem. 2011;286(5):3805-3814.
78. Arachiche A, Mumaw MM, De La Fuente M, Nieman MT. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by a-thrombin. J Biol Chem. 2013;288(45):32553-32562.
79. Arachiche A, De La Fuente M, Nieman MT. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets [published correction appears in PLoS One. 2013;8 (12)]. PLoS One. 2013;8(2):e55740.
80. Milligan G, Smith NJ. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci. 2007;28(12):615-620.
81. Burnier L, Mosnier LO. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of proteaseactivated receptor 3. Blood. 2013;122(5):807-816.
82. O'Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombincleaved PAR1. J Biol Chem. 2000;275(18):13502-13509.
83. Kaneider NC, Leger AJ, Agarwal A, et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8(12):1303-1312.
84. Lin H, Trejo J. Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits b-arrestinmediated endosomal signaling. J Biol Chem. 2013;288(16):11203-11215.
85. Parmar KM, Larman HB, Dai G, et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest. 2006;116(1):49-58.
86. Dangwal S, Rauch BH, Gensch T, et al. High glucose enhances thrombin responses via protease-activated receptor-4 in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31(3):624-633.
87. Pavic G, Grandoch M, Dangwal S, et al. Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. Circulation. 2014;130(19):1700-1711.
88. Salah Z, Maoz M, Cohen I, et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J. 2005;19(1):62-72.
89. Salah Z, Haupt S, Maoz M, et al. p53 controls hPar1 function and expression. Oncogene. 2008;27(54):6866-6874.
90. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem. 2003;278(47):46632-46642.
91. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet. 2011;88(4):450-457.
92. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet. 2012;21(13):3073-3082.
93. Shenker NS, Polidoro S, Van Veldhoven K, et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet. 2013;22(5):843-851.
94. Sun YV, Smith AK, Conneely KN, et al. Epigenomic association analysis identifies smoking-related DNA methylation sites in African Americans. Hum Genet. 2013;132(9):1027-1037.
95. Breitling LP, Salzmann K, Rothenbacher D, Burwinkel B, Brenner H. Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease. Eur Heart J. 2012;33(22):2841-2848.
96. Zhang Y, Yang R, Burwinkel B, et al. F2RL3 methylation in blood DNA is a strong predictor of mortality. Int J Epidemiol. 2014;43(4):1215-1225.
97. Zhang Y, Yang R, Burwinkel B, Breitling LP, Brenner H. F2RL3 methylation as a biomarker of current and lifetime smoking exposures. Environ Health Perspect. 2014;122(2):131-137.
98. Lin Z, Hamik A, Jain R, Kumar A, Jain MK. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol. 2006;26(5):1185-1189.
99. Rosenkranz AC, Rauch BH, Freidel K, Schrör K. Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT. Cardiovasc Res. 2009;83(4):778-784.
100. Rosenkranz AC, Rauch BH, Doller A, et al. Regulation of human vascular proteaseactivated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT). Mol Pharmacol. 2011;80(2):337-344.
101. Compton SJ, Cairns JA, Palmer KJ, Al-Ani B, Hollenberg MD, Walls AF. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem. 2000;275(50):39207-39212.
102. Ma JN, Burstein ES. The protease activated receptor 2 (PAR2) polymorphic variant F240S constitutively activates PAR2 receptors and potentiates responses to small-molecule PAR2 agonists. J Pharmacol Exp Ther. 2013;347(3):697-704.
103. Dupont A, Fontana P, Bachelot-Loza C, et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood. 2003;101(5):1833-1840.
104. Edelstein LC, Simon LM, Lindsay CR, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014;124(23):3450-3458.
105. Edelstein LC, Simon LM, Montoya RT, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013;19(12):1609-1616.
106. Muehlschlegel JD, Perry TE, Liu KY, et al. Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. Am J Hematol. 2012;87(2):161-166.
107. Friedman EA, Texeira L, Delaney J, et al. Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. J Thromb Thrombolysis. 2016;41(4):656-662.
108. De La Fuente M, Noble DN, Verma S, Nieman MT. Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. J Biol Chem. 2012;287(13):10414-10423.
109. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007;5(8):1617-1623.
110. Isberg V, Vroling B, Van Der Kant R, Li K, Vriend G, Gloriam D. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res. 2014;42(Database issue):D422-D425.
111. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289(5480):739-745.
112. Salon JA, Lodowski DT, Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev. 2011;63(4):901-937.
113. Zhang C, Srinivasan Y, Arlow DH, et al. Highresolution crystal structure of human proteaseactivated receptor 1. Nature. 2012;492(7429):387-392.
114. Alsteens D, Pfreundschuh M, Zhang C, et al. Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape. Nat Methods. 2015;12(9):845-851.
115. Padayatti PS, Wang L, Gupta S, et al. A hybrid structural approach to analyze ligand binding by the serotonin type 4 receptor (5-HT4). Mol Cell Proteomics. 2013;12(5):1259-1271.
116. Orban T, Jastrzebska B, Gupta S, et al. Conformational dynamics of activation for the pentameric complex of dimeric G proteincoupled receptor and heterotrimeric G protein. Structure. 2012;20(5):826-840.
117. Tricoci P, Huang Z, Held C, et al; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20-33.
118. Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413.
119. Baker NC, Lipinski MJ, Lhermusier T, Waksman R. Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation. 2014;130(15):1287-1294.
120. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 2012;287(16):12787-12796.
121. Kuliopulos A, Covic L. Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sci. 2003;74(2-3):255-262.
122. Mumaw MM, De La Fuente M, Noble DN, Nieman MT. Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost. 2014;12(8):1331-1341.